{"date":"2025-06-08","count":3,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6838-2025-06-08-2201-1jb07pn","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2025-06-08","time":"22:01:13","subject":"公告本公司與Harrow, Inc.簽署授權協議，授權BYQLOVI(丙酸氯倍他索點眼懸液)在美國的商業化權利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2025-06-08 22:01，「公告本公司與Harrow, Inc.簽署授權協議，授權BYQLOVI(丙酸氯倍他索點眼懸液)在美國的商業化權利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2025-06-08-2159-17n8vbf","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2025-06-08","time":"21:59:57","subject":"本公司終止與Eyenovia, Inc.之授權合作協議合約","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2025-06-08 21:59，「本公司終止與Eyenovia, Inc.之授權合作協議合約」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2025-06-08-1218-1lcoj5z","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-06-08","time":"12:18:52","subject":"本公司治療退化性關節炎之異體間質幹細胞新藥Chondrochymal獲衛生福利部同意執行三期臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-06-08 12:18，「本公司治療退化性關節炎之異體間質幹細胞新藥Chondrochymal獲衛生福利部同意執行三期臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}